AI Brain Scan Tech on Siemens Platform Aims to Revolutionize Alzheimer's Care

SAN DIEGO, CA – March 04, 2026 – In a move poised to accelerate the adoption of artificial intelligence in neurology, Cortechs.ai and Siemens Healthineers today announced a landmark strategic partnership. The collaboration will integrate Cortechs.ai's FDA-cleared NeuroQuant® Lesion Surveillance software into the vast Siemens Healthineers Digital Marketplace, making advanced, AI-powered brain imaging analysis accessible to clinicians worldwide.

The alliance is set to enhance diagnostic precision and streamline clinical workflows, with a significant focus on improving the safety and management of new Alzheimer's disease treatments.

A New Era for Neurological Imaging

At the heart of the partnership is NeuroQuant®, a sophisticated AI platform that transforms standard MRI scans into objective, quantitative data. For years, radiologists and neurologists have relied heavily on visual inspection to assess brain scans, a method that can be subjective and time-consuming. NeuroQuant® automates this process, using deep-learning algorithms to perform automated segmentation of brain structures and lesions, calculate their volume, and track changes over time.

This technology provides reproducible, data-driven insights that were previously difficult to obtain. The latest version, NeuroQuant® 5.0, integrates susceptibility-sensitive MRI sequences, enabling unparalleled precision in detecting even the smallest brain lesions. Its ability to provide longitudinal tracking—identifying new, enlarging, or stable lesions with color-coded overlays—offers clinicians a clear, dynamic picture of a patient's neurological condition.

While traditional visual reads are dependent on the expert's eye, AI-driven analysis demonstrates enhanced sensitivity, capable of detecting subtle atrophic changes that might otherwise be missed. This shift from a qualitative to a quantitative assessment marks a significant step forward in monitoring conditions like multiple sclerosis, traumatic brain injury, and, most critically, the side effects of new dementia therapies.

The Critical Challenge of ARIA in Alzheimer's Treatment

The timing of this partnership is crucial, aligning with the rollout of a new class of anti-amyloid therapies for Alzheimer's disease. While these treatments offer unprecedented hope for slowing cognitive decline, they carry a significant risk of side effects known as Amyloid-Related Imaging Abnormalities (ARIA). ARIA presents as either brain swelling (ARIA-E) or microhemorrhages (ARIA-H) and is a common occurrence, affecting up to a third of patients in some clinical trials.

Managing this risk presents a major clinical challenge. A large majority of ARIA cases—up to 97% in some studies—are asymptomatic and can only be detected through routine MRI surveillance. This places a heavy burden on clinicians to perform frequent, meticulous reviews of scans to ensure patient safety. The risk is particularly high for individuals with specific genetic markers, such as the APOE ε4 gene.

This is precisely where the integration of NeuroQuant® Lesion Surveillance becomes a game-changer. The software, which has received specific FDA 510(k) clearance for ARIA quantification, provides an objective and highly sensitive tool for monitoring these abnormalities. By automatically detecting and quantifying changes in ARIA lesions, the technology empowers physicians to make faster, more confident decisions. This could involve adjusting treatment dosage or temporarily pausing therapy to allow abnormalities to resolve, thereby preventing the development of more severe, symptomatic ARIA.

The ability to reliably track these subtle changes promises a safer path forward for patients, allowing them to potentially maximize the benefits of breakthrough Alzheimer's therapies while minimizing the associated risks.

A Strategic Alliance to Reshape the Market

This collaboration is more than a simple software integration; it represents a powerful strategic alignment between a nimble AI innovator and a global healthcare titan. Cortechs.ai, a leader in specialized AI applications for radiology, gains access to Siemens Healthineers' immense global distribution network and installed base of imaging equipment. For Siemens Healthineers, the partnership enriches its Digital Marketplace, an ecosystem designed to provide clinicians with a curated portfolio of cutting-edge, interoperable digital tools.

By embedding NeuroQuant® directly into the Siemens Healthineers imaging workflow, the partnership removes critical barriers to adoption. Radiologists and neurologists can access these advanced quantitative reports without leaving their existing software environment, a seamless experience that is vital for driving use in busy clinical settings.

"This partnership with Siemens Healthineers marks a pivotal step in expanding access to advanced neuroimaging on a global scale," said Kyle Frye, CEO of Cortechs.ai, in the official announcement. "By combining our innovative AI technologies with Siemens Healthineers' unmatched reach and imaging expertise, we're equipping clinicians with faster, more precise insights to make better-informed decisions around Alzheimer's and ARIA care."

The sentiment is echoed by Siemens Healthineers, which views the collaboration as a core part of its mission to advance precision medicine.

"We are excited to welcome Cortechs.ai's NeuroQuant Lesion Surveillance solution to our Digital Marketplace," stated Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers. "This collaboration underscores our commitment to providing clinicians with advanced, interoperable tools that enhance diagnostic confidence and streamline workflows. By integrating NeuroQuant's proven capabilities for supporting ARIA surveillance into our ecosystem, we empower healthcare providers to deliver more precise and personalized care for patients undergoing Alzheimer's disease treatment."

The Future of Integrated AI in Healthcare

The alliance between Cortechs.ai and Siemens Healthineers serves as a blueprint for the future of medical technology, where specialized AI solutions are no longer siloed but are deeply integrated into the foundational platforms that hospitals and clinics rely on daily. This model addresses the critical 'last mile' problem in health tech innovation: ensuring that powerful new tools are not only effective but also accessible and easy to use.

While the immediate focus is on ARIA and Alzheimer's care, the potential for expansion is vast. Cortechs.ai's portfolio includes AI modules for other neurodegenerative conditions, and the success of this initial integration could pave the way for a broader suite of AI-driven diagnostic tools on the Siemens platform.

Ultimately, this partnership signals a maturation of AI's role in medicine. It is moving from a promising but peripheral technology to an indispensable component of the clinical care pathway. By providing objective, quantifiable data at the point of care, this collaboration aims to elevate the standard of neurological diagnostics, improve patient safety, and help realize the full potential of next-generation therapies.